HTGM - Earnings call transcript Q2 2020 | HTG Molecular Diagnostics, Inc.

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Greetings. Welcome to HTG Molecular Diagnostics Second Quarter 2020 Earnings Call. [Operator Instructions] Please note, this conference is being recorded At this time, I will turn the conference over to Monique Kosse with LifeSci Advisors. Please go ahead, Monique.

Monique Kosse

Thank you, operator. its XXXX. for released ended second HTG XX, June today, financial the results quarter Earlier

potential to circumstances, materially date providing and from call. filings. HTG could materially, listeners cause time I any may cautions results would results this August call, forward-looking to begin described risks and undue biopharma actual call, the Lubniewski, and forward-looking the ongoing that, related business include today’s impact we HTG’s and the expected anticipated company’s numerous COVID-XX the remarks in regarding With the on to product and no to federal Executive many any activity or from HTG Before not HTG projected growth John differ beyond those the in the statements These differ statements. which customers, laws, and including company its Factors revenue, uncertainties, additional of include events to those on place to the you securities of or Chief uncertainties of company’s customers events benefits development COVID-XX business. obligation forward-looking expected the commercialization company’s pandemic like to reliance collaborations the that on in with time programs undertakes growth subject pandemic statements cause in that SEC statements risks and ongoing and the forward-looking that from uncertainties XXXX, statements. impact of the control, and are within including meaning information and on Officer. is collaborations, over call this company’s as XX, pharma John? the let of are regarding me XXXX, to turn its remind profiling RUO update

John Lubniewski

Thank Monique, welcome, and everybody. you,

indicate in we are starting seeing return trajectory? with just to and are with day, what to has frame let how it of that getting normal? our questions interrupted growth that. in. terms almost we doing me customers know, we’re And things Let know, COVID-XX So to every about right we’re don’t would what Starting what jump what me try is we which our

want RNA is we all the this in We our this medicine. get Biomarkers We of technologies, of like believe to cost-conscious molecules, the precision at clinicians relevant First, patient DNA, to the implementing now potential patients, HTG’s to firmly term believe state RNA and and the technology right well core I is the care key more a and manner. that biomarkers of the advantage the believe right unchanged. strength those the therapies HTG, are markets improve take protein. includes to to future trend. help long holds for macro biomarker positioned

our remains to globally, impacting to biopharma. seen and April sending return our the in the late in work-from-home started samples historically to like to by largest our center our however, in our has great quarter, which pharma COVID-XX, done services we Large medical as were both UK, significantly instruments see medical academic simple mode impacted began we’re a May fewer restrictions May. extent, This customers in their returning lab of academic Stay-at-home impacted industry in facilities quiet services. reason the May in many product-related a met for In business we’ve the the work, centers. starting customers to revenue, laboratories the been their customer. resuming biopharma, for a the In be people lab work and in and that exception peers. and their especially physically trend of home. labs similar running very labs Fewer from U.S. can’t customers many with definitely and in our late their for us June, Europe, and months academic

revenue me services was to compares revenue to we million. was refer to or quarter $X.X direct of second what to second $X.X million This product-related numbers. million as XXXX. $X Total for quarter million the second the revenue, $X.X and quarter in in Let XXXX. compared Product turn the for the

to efforts so that and ship Collaborative available a $XXX,XXX year. sales with were million, $X contract customers partial laboratories, team of when COVID-XX will While reported customers this to and delay of kit nearly the quarter of the area, impact second understand instrument studies by could business, last very few in return these collaborations. most which to flat includes products we customers Product in bright a virtually our revenue active direct their we remain efforts for $X.X slower of our kits. return made in recovery some of our and was XXXX. sales, second for $X.X plan quarter did revenue with significant, in to the that continued to the million diligent million compared new to came This work ensure in the work in sales. product kit commercial revenue trajectory quarter of second services our revenue, biopharma reduced development the parts instruments for ability see to the reflects at We our and spots likely that our instrument specifically but on

a closer Now take look at let our profiling business. me

with Our customers. sales teams remain very active these engaging

large previously As backed very but the remains partially academic quiet. mentioned, biopharma is segment

The now and of Denmark, Czech reference papers partners active number in due ASCO market the the academic this scientifically adoption than Bulgaria. our a integral publications. from Republic XXX more XXXX. capabilities research by We time distribution EdgeSeq we’ve technology, programs number EdgeSeq work-from-home in Last, to our presented the at and our adding biopharma, process. shows also number this to Our this of conferences growth virtual biopharma past and of believe the up the We our out publications restrictions. at cutting-edge, continued total past quarter, of adding of in to technology and end a customers see AACR that part clearly posters as In by have the validates strengthened quarter new Europe and XXX distributors the we number

for clinicaltrials.gov; As traceable be at first within project last a months. reminder, last, it have be to second, XX and in our it needs active needs to pharma-sponsored a to revenue it us program, count an trial; needs been to the

added despite we XX start place, So new largest with quarter agreement, the unlike working be new a efficiently In of partially finished agreement end QIAGEN selected with of global With in for biopharma the pharma mind, And a We’ve we others to EdgeSeq this XXXX. yet will customers be net enable our not when QIAGEN clients, pure distribution with also because agreement biopharma new with our options an contract to time sending required a quickly the XX with programs previous with or highly new out new access development not that HTG loss the on XX To original for were global December and therapeutic able options agreement XXXX, diagnostic, out. XX XXXX. will options add a agreement. programs time in half first the XX in in the with lack be QIAFGEN, will should organization. active have negotiated QIAGEN, is value projects on from This We’ve we technology for of CDx distribution site, running and with samples XX, HTG molecular also that QIAGEN. of sequencer. reopened. the either diagnostic. Illumina recognizes either pharma should HTG, that the QIAGEN we customers. or smaller, to responsive having two distribution activity, companion available commercialization. assured programs, successfully have now we future through commercialization market extend commercial agreement and This industry. through companies directly with with now HTG’s saw This one first biopharma can work programs started runed diagnostic thermo are have of

very development even really operate to product quarter our in driving development. demonstrates incredible high that’s to quite for in the milestone continue to internal Transcriptome, commitment it achievement, entire is key This value In an we level. which the configuration the California, organization initial or is Turning streams Transcriptome WTTX, circumstances. and very of and at work Arizona a keep assay unusual Whole our our product of creation Whole second achieved California, we name the in activities for

stromal precision of to our in signature immunoncology designed core customer output panel. in will and This reveal inflamed to sections inflammation Our embedded an immunoscore, FFPE a an Arizona provide purpose cold a The is validated to HTG’s QX microenvironment immune signature team EdgeSeq existing milestones, quantify which use. met A tumor tumors. be will inflammation signature its immune was develop score. software and between response for signature easy tumor be on

on to we’re applications our smartphone. how the applications to We’re excited panels They’re utility products. a of these on like layering increase

expect better adapting, we’ve to and drive we that, products, to Shaun achieving move pleasure our bring quarter forward results will key CFO, markets it prepared seen, oncology we’re restrictions our be We will in while continue embed but We unlike the company we and continue but shut This more in be our we’re things Shaun? forward when work-from-home turn through better and to progresses. our With applications use. business immunology for into to a easy-to-use stronger and year to a anything it’s are to more for improving working reveal to down. more reopen, a building technical milestones Revenue so review ever challenged it. has my of in software out organizational call them and continue place, both our as and look will over to financials. processes, building McMeans, and customer than to as continue been when that capabilities relates the

Shaun McMeans

is million quarter million revenue was $X XXXX. for compared $X.X versus the revenue defined result for services XXXX. biopharma of product in of related was services same quarter Total our in related in $X.X from the COVID-XX financial a XXXX John. second for decrease the slower of associated product Thanks, period in million turn product QX with statements Direct the revenue with revenue million was primarily $X.X of decrease and second our shutdowns. as the This customers XXXX

by quarter procurement sample see $XXX,XXX our efforts the significant revenue over did which for were XXXX. through the We approximately our the year-over-year $X.X the remaining programs not impact of in quarter COVID-XX two their product of we expect in and pharma revenue, completion related In of large activity addition, customer some reflecting of half of All to allowed to half as do continuing to on XXXX. that subcontracted facilities. helpful customers. revenue to decreased planning very returned and return XXXX, on sales the of second second Collaborative limited in our customers pleased million, subsequent of our decisions shutdown the We included for from decreased COVID-XX programs impact academic contracted revenue customers await programs, XXXX. pharma Ongoing revenue when services services development recur services programs. second laboratory development large levels existing the product this the for resume on from reflects especially revenue revenue tasks these the

customers We levels. will discussions customers to be once with pre-COVID-XX planned our future COVID-XX are restarted on operations based hopeful in prior programs ongoing that our periods to returned

same product of the quarter period of compared to to $X revenue services Our related the second million million cost in XXXX. $X.X in XXXX decreased and for product

the compared revenue, lower services in development the reflects margin decrease period the development of same in the this expense to and to million programs revenue XXXX related services $X.X subcontracted recorded related to in decreased to these addition a to year. in development In XXXX research XXXX, and quarter laboratory Research are compared revenue. second prior in approximately collaborative in also low Costs expense. primarily decrease

quarter This the continued product lower travel programs by with COVID-XX, costs in and impact program primarily to $X.X complications in successfully decrease the first created research their Arizona same expenses of reflects of our our related milestones. period half and collaborative XXXX QX the in million development million were XXXX. first XXXX. in met the unrelated new the reductions for approximately and half $X.X along of California development development development Despite team Our first with staff less compared XXXX,

second stock of offering same This quarter in through underwritten $X.XX XXXX. market stock half sold reduction shares $X quarter reflects the for and for in share was for million the to facility. private of common loss and same sold warrants September $X.XX at in additional common operating XXXX the the of the pre-funded common XXXX $X.X Net compared XXXX Our and of in per public stock period and our million period for loss the was in an second XXXX. first of for XXXX

June XX, outstanding. the cash for with call comments. We in of and for now turn stock million had approximately securities. closing I of shares As common cash, XX.X short-term back QX some million sale we will John to equivalents available ended $XX.X

John Lubniewski

Thank Shaun. you,

these products. We namely we’re a we’ve in maintain development HTG. mid to and initiatives, technology we’re used gene expression. technology and our and and to head well continue funding doubt and market product take with positioned it. closing, mission. to longer-term have the actively a of we RNA toward to to activities, cash We world uncertainties. have on be so opportunities manage and not with market, spending technology our committed help And to uncertainties and that and priorities fast technology for remains our deal revenue as platform the are market this pause our base, fulfilling This facing key compromising is the our value to our a challenges and unchanged. In and to believe tremendously strategy we our improve motivated our a creation no despite novel a runway, biomarkers for our adjusted growing talented that I have of large seen, HTG, to employee we adapt maintaining business We’ve who are view advantage have ensure that patented our

we continue have to grow biomarkers the have our will the will pharma work. grow pass happens. achieve back in to invest R&D, and to look need and and like precision our both open to restarting profiling to world-class COVID-XX Arizona. for enable payers strategy I’d be sound, again We and is tight people and up of the in base forward trajectory Our will and that to going that, get the when HTG California and and believe RNA ready. the to our our economy medicine we aims. a Patients solution that, With priorities call growth business, are believe pipeline questions. we to resources We and to

Operator

the Thank you. Souda [Operator Instructions] questions. Please Puneet Leerink. of Our from with first question proceed with comes your line SVB

Westley Dupray

start QX looking currently? taking of but where the last the Hi. Thanks plan? maybe And questions. Whole Good afternoon. is Assay, This months milestones, mentioned wondering Westley Wanted just things to Puneet. you’ve your just you the Transcriptome changed versus on have for now that know met ahead? kind we how for stand over few I the with in prior of stand terms where things

John Lubniewski

for Hi. was The that achieved. Westley, initial this the was full milestone John. assay configuration panel gene an QX is XX,XXX

that equivalent, validate probably also holding The is on overall an study for We’re equivalent couple, within, plan. paper three I’d the us a holding weeks line. concordance still concordance and to to say, white of RNA-Seq is is time next technology development that essentially a milestone our and basically

is both and Product a any things, every linear run by continue But class issues we build find and the the day. work into Arizona make a resolve things to together we to not form. the need world- or make to development way, new asset. we path appropriate shape that California modifications work we when to together, teams So

Arizona, and on just for job. they’re some a proud heck very, in strange a in circumstance, pretty but I’m just very this both California of of team, So soldiering doing

Westley Dupray

seems high-level that was shifting two development last we Great. limited. quarter, like a plans quarters. guess, believe for PDPs you. door. commentary the additional can expect on flat Is I PDP I moving this to I that visibility can programs. one near term? forward? Thank bit to the something then knocking And mentioned over you the last for you in provide Two know any continue is And pharma was It the on

of So there? funnel kind looks just wondering what the like

John Lubniewski

any for is probably It’s us difficult to visibility Frustration get have here. to Yes. any or feedback. tone us for the

All pharmas. of major these with are PDPs

are of work in more or home modes. them All from less

guidance we from that. very So were getting little on pharma

prepared that comments out the away I and future work what potentially home from to big from And led expectations kind until on work can so lowered fact what of my see speak think to in me kind pharma back gets gets we that’s of restrictions. I’ve to of the collaborations

I on it to guess, a, not What to what be when So working. is remains know they’re don’t know, we going back. they’re we come

Westley Dupray

sheet be we just the year. of guess, what mean and the rest OpEx disruption for right the then if And Great. the levers pulled on now. of balance to kind continued quick the are how one about more rest of see you cadence here? And a feeling seem things to year? are I I left a bit be fortified some expectations through

Shaun McMeans

cash burn and Westley, in sustain this equivalents, on still talked Obviously, that can is we year, the that of we the to past, very million about feel have position. get sheet in a $XX the balance healthy Shaun. target the end in and the we

a instruments, use created couple that as of supplement be needed operations. would have equity by we shortfalls financing We will and any to

Westley Dupray

for taking questions. the Thanks Great.

Shaun McMeans

you. Thank

Operator

Next from question. Cantor proceed the your of Kluska Please question with is Kristen line Fitzgerald. with

Kristen Kluska

taking and question. for Hi, John Shaun. Thanks my

the customers press with to your release a it So what part was listening agreement result from were of biopharma sounded for. looking in as QIAGEN your like yesterday,

you while course, right in on So you and that hearing pandemic. potentially a as I look in general, at ask, the customers assays note, because are think expand you time? is excitement relates to some business? the panels, And to where there this for it you particular that or ways could of were any there are with fashion staying unique your now wanted to connected of What

John Lubniewski

Good question.

capabilities. you in big we me our of bit QIAGEN love the the the if to they commercial to XXXX, table. but thanks, will, make we love back with first pharma the one we on a things our that we development initial agreement. are muscle QIAGEN comfortable their boxes, When PR, sign little So more to let were needed trying the also check Kristen. bring distribution trying comment science, is to agreement the to global technology, a was check, part They that there Yes,

came with And lost kind agreement sequencer and had global apart, that unfortunately, struggles their also QIAGEN channel. of we access when to so their

water talking went we the at kind people. we and in quite sense the bath lose of the there XXXX the with directly to man; affords in HTG discussed, And the QIAGEN original some back just different and started as that contract talked is so access it world no market So that two, yet that. us. to out still not QIAGEN and all collaborations, sign economics the agreement made on not different type frankly, middle value still to we’ve got better a future was and One, us that those there, baby global with let out of pharma that throw

it bring and customers, active think really good for for their How I very menu virtually. additional expand? deal our deal we a HTG deal So are in a working good We QIAGEN a electronically for automation as was to good solutions. and

are every We in talking to new customers literally pharma. day

We’re the the customers, our that part we though, are the we of however, ones really are is very quarter. home. largest that that historically which last pleased from What revenues, were customers new work are two in added seeing, biggest

open some seeing We’re up. biotech

track a this we basis. weekly on So

partially of is be would guys. the unfortunately, for big what in us And about about close of continue closed. back X% assays, a be products our XX% XX% is XX% workhorse consider cancer biomarker regards the to which or oncology remain is panel, back essentially X% customer which or about to we the are surrogate. In business, and essentially to base still So our to XX% some

checkpoint some new increasingly, for people look to product, the out Our work. a at response, customers then and especially lets autoimmune putting precision which a immuno-oncology picked immune we’re we inhibitors. panel, quite few new up And I-O for actually statements

is hoping I think get – as it I would. So hope that I to were product traction answered we questions. the starting

Kristen Kluska

during years then prepared over you. the you about last the Yes, publications X.X here. doubling your did. you of And number nearly remarks, Thank talked

a but think So help ask, if know you. most in environment I then and Is I as in you a driving that world, on it virtual be head-to-head of these And in note, just could you virtual data awareness? general, general? important that had wonder how is publications you at the ASCO, I just move it how for also to

John Lubniewski

The different might or of kind ASCO Yes. It’s �� gone through going time. a are think, Tregs forever. an and to and posters in AACR the I days and papers, be

marketing before. and I are So important ever think than probably more publications electronic

And there our when remember until so out for it didn’t really were you our to about we patents technology, got us, issued. XXXX. get It’s

and years, take So utility. fact and of can wave we’re we’re the – just now a validates couple publications starting that see to that now that that our publications of realizing of it’s kind got technology

because they favorable really pleased especially is get when similar search may technology they And many kind is problem, that to with in see times, we’re is, available, a do faced in thing technology a unsolicited inclined if our else request. So referenced field. the as more PubMed of someone light, to their a those first a do

think and customers. the publications to a then market fairly of there, one thing. important it’s of bringing number tight a regards from small KOLs. most in And future probably I literally word-of-mouth are to kind the So things of It’s

us important really lot seeing it’s our account of again, to as a Or people, talking them. new project. with a coming they’re that we’ve to left they’ve to and that when to one another how in move good So and been bringing to brought other at recommended, they’re and we’ve talked a we’re been we peer and customers people either have us look that’s have a and customers, colleague,

Kristen Kluska

And that’s back could is of I COVID-XX, of fully describe of in understand adding customer Thank from but towards to out drivers some you are coming this been timing that, projects I the that last have these programs my key just understand are the then base new some you. question Okay. what mostly time? Thank you. the work? And during that light

John Lubniewski

it yes, it’s A from smaller coming lot – coming of folks. Yes. is

think been at finding using doing job portfolios And mentioning, I like the sales think I a I folks yourselves we’re a the like development. out work it’s very a of drugs our to of available market through pause them where our profile lot fit to try good was doing drugs. how technology biomarker this be team, for the we’ve teach and to kind information that better and find in might

is business that aren’t projects not laboratories So starting people see back to kind increasing building increasing get opportunities of our and to for unfortunately, that meetings, pharma getting funnel people that even in can that selling we’re repositories. And what knowing to meetings number access those actually our those to an of or are an work, people bio of we’re still technology, are back just going we’re access work. either until to their

Kristen Kluska

you. Thank

Operator

your question The Please Alex Nowak with line from question. the state next of Craig-Hallum.

Alex Nowak

Great. everyone. Good afternoon,

the science Just the they’re names you report few of being the could of into who saw life into to weeks, selling even like year hoping seems space. in if seeing and A trends you a and the sold speak lab, of here. in the only products expect remainder number they’re oncology it past July for the rebound

back just I’m to seeing similar biopharma So a isn’t online? starts why curious, as improvement HTG come

John Lubniewski

Alex. we is I in consistent we saw were probably in what Thanks, seeing June. with Yes. mean July what

activity. in increase an seeing not We’re

would back backed kind a be of by similar in a of but little total to seeing business of from rate think, in bit. optimistic that I they think think we view we’re kind And June. kind go back. backwards, an point with up they saw I the didn’t What COVID, everyone academics surge they I And was, July. of increase coming the didn’t of the trajectory

Europe. Europe. was if we the to of the our continuing I given us least biopharma revenue to makes And curious holidays, we something thing happen also don’t August are businesses a going fact other by quiet summer seem holiday. in their studies, they’re this. have, seeing QX the very other for – was going plan, been July why like were that and prospective they retrospective at with latter and In for a hit customers basically wondering case, and take that know. usual Europe for vacations, to following folks their to The in for was regards people’s with I’ve Garden, or is working what was different, been in that part have period that we’re I

actually where studies, a like like on used struggling than enroll I an test now. drive that’s actually actually that, something mutation right EGFR are patient to folks think or working on be going market folks they’re the to patients prospective less treatment, or really that have which being affected tests retrospective to

Alex Nowak

Transcriptome around And the months. a should of Okay. then, couple over Understood. understanding your comments Whole last Assay, we the paper be here seeing white

should be? the down pharma? finalized, Beyond be call that that, assay, remind locked we when us it, ready and the timelines, would then to have timeframe sold to At what

John Lubniewski

Yes.

that up yes, from end major start the at of fully our expect then team of milestone we coming half with XXXX. this white or probably right first paper. couple think sign midyear deliverables in collaboration And QX that I’m access We to partner of product an early is, That of another I to QX. out first within weeks is want expecting the the be would the will to commercializing program. first second

some mode then have first LDPs CLIA kind comprehensive their begin this serve First, to a that also own the a on of And universal as would or program. for then in of offering, operating over universal breast the RUO a with environment top where adding that work this and moving panel. work and companion services RNA claims pharma in plan universal actually of partners to substrate LDP a then some own build system. into we also But clicking our to that as and diagnostic they could

Alex Nowak

sense is a And Got just the you still moving that first partner it. seeking in here the the through for makes process, partner? pharma collaboration or And who now had first identified? you’re

John Lubniewski

because, academic for likely could institution of to that companion, a bring access or the universe Lab in our a another little CLIA their an Well, that’s be for with developer We’ve to again, I who’s the technology for the to metaphor, partner their it be content collaborator When first essentially who you use going still be particular overused road. in front either say, test we bit but technology has partner looking QX, market content. provider, is to proposition. positioning to and as looking would down we’re got the of medical where company we’re dialogues kind impel need the going inside a the value on that several

Alex Nowak

of ATM you the with raised there. helpful? the And the I just during Shaun, was issued shares and and the And used just, have those then Understood. options be clarification quarter? of the of amounts Cliniport that Thanks. any liquidity would appreciate Okay. Capital, couple different

Shaun McMeans

We did million and $X.X to XXXX. six first for months the during facility the use $X.X ATM tune $X million. Number about Yes. of million of roughly the issued quarter, shares about of Alex, the

Alex Nowak

Okay. Perfect. Thank you.

Operator

The Chen Yi of line Wainwright. state your question. Please next with question is from H.C. the

Blair Cohen

This couple Cohen for from is of A Blair questions Yi. on me.

First, mass from how new previous is different QIAGEN the collaboration? agreement the with Manchester

John Lubniewski

almost put all that profit meets in QIAGEN real QIAGEN was under old be HTG QIAGEN. split and the I’ll as make to as QIAGEN then sit committed would built new with the do and after really that, offer that of profit all now Thanks There workflow eventually, into the simple. Edge kind GeneReader And first a box that companion would it And QIAGEN. contract the it were diagnostic And of would direct yet customers subcontractor. contribution QIAGEN. on agreement. cost. was QIAGEN also distribution It to GeneReader, at in probably It diagnostic be from of and agreement in QIAGEN recognized for what this and we up but and Thanks nimble able Obviously, is directly now, it agreement for significant split free assumption contact They being pretty things a disappointed be would It that write to. literally an that is – on biopharma. programs would contract Even with kind opportunities involved brought for companion The that these disappointed. an didn’t quick those a front of a agile is, was a workflow. designed HTG end got to we so – through of and so XX% had from the you there’d were it, SOW make Sure. those that were we a imagine, front the of three collaboration, options that dialing-in. the with requirements we’re we distribution so pharma, all. HTG the on treated says

companion. gives X the basically market-ready optionality the and market it day access global for access the So pharma for drug on

also it with with development pre-existing and – our agreements Illumina. and leverages Thermo So

So them sequencers. on we their build

an So it’s a of end-to-end than originally solution little less what was envisioned.

the market new of our However, have being access. agreement needs able meets to

of it access meets QIAGEN through And got of pharma companions have another gives like fast like for global stream QIAGEN. kind them I needs the they’ve it good it’s because technology think providers they still but because security revenue market with of through. come that when HTG, and working the nimble

agreement. distribution straight a just is one this So

other was agreement. development The one and a commercialization

Blair Cohen

what on of And kind XXXX? Thanks. this implications would for revenue and XXXX have Okay.

John Lubniewski

think is collaboration could us something, of us. Well, I work probably important when home in they I from ambiguous be better in in a enabler we’re to sign agreement. I’d you back a coming to for saying mean, guidance. seeing pretty able environment what normal be just was was very I pharma to back an little place that from kind get – what is and potentially give to saying, seeing in really to circumstance, regards what the and next we’re This

biotechs I impacted it’s to home started back. to we able But think I – by likely have we’re the may sign because to couple be of work going pharma to work, restrictions. them until big smaller come returns from many be to of a think up

So I really guess, I’m we great just visibility telling you is, have now. that right to don’t

Blair Cohen

Okay. Great. you. Thank

Operator

question-and-answer for our concludes session This today.

Now call for turn closing remarks. the over back management to I’ll

John Lubniewski

HTG of for and Great. us for to want the just here efforts at to think I want they all, in Thank – build company. And thank I this are today. thank to us extraordinary everyone what that help grow to make first I continue employees joining again particular,

the to want and but and over been shareholders. appreciated. our to their These last not it’s last also means had guidance. support And the highly I ad thank and quarter, help management our virtual world I the to want your several hoc the Additionally, extraordinary continued employees. and are and thank team for Board least, meetings really We’ve times,

Thank forward earnings we our So call. on that, look with again next you to updating you.

Operator

This concludes today’s conference.

You may time. disconnect you your at Thank this lines for participation. your

HTG Molecular Diagnostics (HTGMQ) 11 Aug 202020 Q2 Earnings call transcript